Thursday, October 30, 2014 11:33:05 PM
http://www.biospace.com/News/ebola-clinical-trials-big-name-players-in-the/350579
in Philadelphia, Hemispherx Biopharma (HEB) focuses on treating and preventing chronic viral and immune-based disorders. The company's flagship products include Alferon N Injection and an experimental immunotherapeutic dubbed Ampligen. On September 29, 2014, the company announced widening its research collaborations to develop therapeutic cocktails against Ebola virus.
Ampligen and Alferon are presently in the lab testing phase in eight labs in the U.S., Western Europe, and Canada. It is in the discussion phase in West Africa with various government officials.
FEATURED Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • May 17, 2024 11:00 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM